ofloxacin has been researched along with Uterine Cervicitis in 16 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Uterine Cervicitis: Inflammation of the UTERINE CERVIX.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The clinical efficacy and safety of levofloxacin (LVFX) 500mg qd were evaluated in female patients with cervicitis with Chlamydia trachomatis and intrauterine infections." | 9.15 | [Clinical study of levofloxacin 500 mg qd in the treatment of cervicitis and intrauterine infections caused by Chlamydia trachomatis]. ( Ando, Y; Fujiwara, M; Hoshina, S; Izumi, K; Kinoshita, C; Kurashima, M; Mikamo, H; Nakabe, K; Takahashi, K; Yamagishi, Y; Yoshimura, M; Yoshioka, M, 2011) |
| "An investigation was carried out to determine the therapeutic effect of levofloxacin (LVFX) once-a-day oral therapy at the dose of 200 mg/day for 7 days on uterine cervicitis, in comparison with LVFX twice-a-day oral therapy at the dose of 200 mg/day for 7 days." | 9.09 | [Effects of levofloxacin once-a-day therapy on uterine cervicitis]. ( Hayasaki, Y; Ito, K; Izumi, K; Kawazoe, K; Mikamo, H; Sato, Y; Tamaya, T; Yamada, Y, 1999) |
| "To compare trovafloxacin, a new quinolone antibiotic with enhanced activity against Neisseria gonorrhoeae, with ofloxacin as single-dose oral therapy for uncomplicated gonococcal urethritis or cervicitis." | 9.08 | Randomized trial of trovafloxacin and ofloxacin for single-dose therapy of gonorrhea. Trovafloxacin Gonorrhea Study Group. ( Dalu, ZA; Johnson, RB; Jones, RB; Leone, P; Schwebke, J; Thorpe, EM, 1998) |
| "Fifty-eight males and 34 females with nongonococcal urethritis and/or cervicitis were treated to compare the efficacy and safety of 7-day regimens of oral ofloxacin 300 mg twice daily and doxycycline hyclate 100 mg twice daily." | 9.06 | Randomized comparison of ofloxacin and doxycycline for chlamydia and ureaplasma urethritis and cervicitis. ( Beville, R; Holmes, B; Lutz, FB; Mogabgab, WJ; Murray, M; Tack, KJ, 1990) |
| "Efficacy and safety of ofloxacin (OFLX), a new quinolone antibacterial agent, were investigated in cases of sexually transmitted male urethritis and cervicitis." | 9.06 | [Efficacy of ofloxacin in sexually transmitted male urethritis and cervicitis]. ( Aso, Y; Higashihara, E; Hirose, T; Kishi, H; Kiyota, H; Kumamoto, Y; Machida, T; Okazaki, T; Sakai, S; Tsunekawa, T, 1988) |
| " The effects of levofloxacin administration at a dose of 300 mg/day for 5-14 days were investigated in the subjects (n = 66) after the discussion of cystic cervicitis." | 7.69 | [Measurement of antibody titers to chlamydial infection and effects of levofloxacin in cystic cervicitis and chlamydial infection]. ( Chimura, T, 1997) |
| "An investigation was made on the concentration of levofloxacin (LVFX) in cervical mucus and its clinical effects on cervicitis." | 7.69 | Concentration of levofloxacin in cervical mucus and its clinical effects on cervicitis. ( Arai, M; Chimura, T; Kawagoe, S; Kunii, K; Matsuo, M; Morizaki, N; Murayama, K; Numazaki, M; Oda, T; Onuma, Y; Saito, N; Saito, T; Sato, F, 1997) |
| "Sexually transmitted diseases are an important cause of morbidity in women." | 6.38 | The clinical experience with ofloxacin in the treatment of sexually transmitted diseases. ( Corrado, ML, 1991) |
| "The clinical efficacy and safety of levofloxacin (LVFX) 500mg qd were evaluated in female patients with cervicitis with Chlamydia trachomatis and intrauterine infections." | 5.15 | [Clinical study of levofloxacin 500 mg qd in the treatment of cervicitis and intrauterine infections caused by Chlamydia trachomatis]. ( Ando, Y; Fujiwara, M; Hoshina, S; Izumi, K; Kinoshita, C; Kurashima, M; Mikamo, H; Nakabe, K; Takahashi, K; Yamagishi, Y; Yoshimura, M; Yoshioka, M, 2011) |
| "Women with clinically diagnosed cervicitis and BV received doxycycline and ofloxacin and were randomized to treatment with metronidazole gel or placebo." | 5.10 | Interrelationships of bacterial vaginosis and cervical inflammation. ( Schwebke, JR; Weiss, HL, 2002) |
| "An investigation was carried out to determine the therapeutic effect of levofloxacin (LVFX) once-a-day oral therapy at the dose of 200 mg/day for 7 days on uterine cervicitis, in comparison with LVFX twice-a-day oral therapy at the dose of 200 mg/day for 7 days." | 5.09 | [Effects of levofloxacin once-a-day therapy on uterine cervicitis]. ( Hayasaki, Y; Ito, K; Izumi, K; Kawazoe, K; Mikamo, H; Sato, Y; Tamaya, T; Yamada, Y, 1999) |
| "To compare trovafloxacin, a new quinolone antibiotic with enhanced activity against Neisseria gonorrhoeae, with ofloxacin as single-dose oral therapy for uncomplicated gonococcal urethritis or cervicitis." | 5.08 | Randomized trial of trovafloxacin and ofloxacin for single-dose therapy of gonorrhea. Trovafloxacin Gonorrhea Study Group. ( Dalu, ZA; Johnson, RB; Jones, RB; Leone, P; Schwebke, J; Thorpe, EM, 1998) |
| "Fifty-eight males and 34 females with nongonococcal urethritis and/or cervicitis were treated to compare the efficacy and safety of 7-day regimens of oral ofloxacin 300 mg twice daily and doxycycline hyclate 100 mg twice daily." | 5.06 | Randomized comparison of ofloxacin and doxycycline for chlamydia and ureaplasma urethritis and cervicitis. ( Beville, R; Holmes, B; Lutz, FB; Mogabgab, WJ; Murray, M; Tack, KJ, 1990) |
| "This study compared doxycycline with ofloxacin in the treatment of nongonococcal urethritis in men and mucopurulent cervicitis in women and compared both drugs in the treatment of infections due to Chlamydia trachomatis in both men and women." | 5.06 | Efficacy and safety of ofloxacin in the treatment of nongonococcal sexually transmitted disease. ( Batteiger, BE; Jones, RB; White, A, 1989) |
| "Efficacy and safety of ofloxacin (OFLX), a new quinolone antibacterial agent, were investigated in cases of sexually transmitted male urethritis and cervicitis." | 5.06 | [Efficacy of ofloxacin in sexually transmitted male urethritis and cervicitis]. ( Aso, Y; Higashihara, E; Hirose, T; Kishi, H; Kiyota, H; Kumamoto, Y; Machida, T; Okazaki, T; Sakai, S; Tsunekawa, T, 1988) |
| " The effects of levofloxacin administration at a dose of 300 mg/day for 5-14 days were investigated in the subjects (n = 66) after the discussion of cystic cervicitis." | 3.69 | [Measurement of antibody titers to chlamydial infection and effects of levofloxacin in cystic cervicitis and chlamydial infection]. ( Chimura, T, 1997) |
| "An investigation was made on the concentration of levofloxacin (LVFX) in cervical mucus and its clinical effects on cervicitis." | 3.69 | Concentration of levofloxacin in cervical mucus and its clinical effects on cervicitis. ( Arai, M; Chimura, T; Kawagoe, S; Kunii, K; Matsuo, M; Morizaki, N; Murayama, K; Numazaki, M; Oda, T; Onuma, Y; Saito, N; Saito, T; Sato, F, 1997) |
| "Ofloxacin was successful in eradicating C." | 2.67 | Effectiveness of ofloxacin in the treatment of Chlamydia trachomatis and Neisseria gonorrhoeae cervical infection. ( Faro, S; Hammill, HA; Maccato, M; Martens, MG; Riddle, G; Roberts, S, 1991) |
| "Sexually transmitted diseases are an important cause of morbidity in women." | 2.38 | The clinical experience with ofloxacin in the treatment of sexually transmitted diseases. ( Corrado, ML, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (18.75) | 18.7374 |
| 1990's | 9 (56.25) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 2 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Woods, JL | 1 |
| Scurlock, AM | 1 |
| Hensel, DJ | 1 |
| Mikamo, H | 2 |
| Yamagishi, Y | 1 |
| Takahashi, K | 1 |
| Izumi, K | 2 |
| Hoshina, S | 1 |
| Nakabe, K | 1 |
| Fujiwara, M | 1 |
| Yoshimura, M | 1 |
| Ando, Y | 1 |
| Kurashima, M | 1 |
| Kinoshita, C | 1 |
| Yoshioka, M | 1 |
| Ye, LL | 1 |
| Zhang, BY | 1 |
| Cao, WL | 1 |
| Chimura, T | 3 |
| Jones, RB | 2 |
| Schwebke, J | 1 |
| Thorpe, EM | 1 |
| Dalu, ZA | 1 |
| Leone, P | 1 |
| Johnson, RB | 1 |
| Arai, M | 1 |
| Onuma, Y | 1 |
| Oda, T | 2 |
| Kawagoe, S | 1 |
| Kunii, K | 1 |
| Saito, T | 1 |
| Saito, N | 1 |
| Sato, F | 1 |
| Numazaki, M | 1 |
| Matsuo, M | 1 |
| Murayama, K | 1 |
| Morizaki, N | 1 |
| Chandeying, V | 2 |
| Skov, S | 1 |
| Kemapunmanus, M | 1 |
| Law, M | 1 |
| Geater, A | 1 |
| Rowe, P | 1 |
| Sato, Y | 1 |
| Hayasaki, Y | 1 |
| Tamaya, T | 1 |
| Yamada, Y | 1 |
| Ito, K | 1 |
| Kawazoe, K | 1 |
| Schwebke, JR | 1 |
| Weiss, HL | 1 |
| Morisaki, N | 1 |
| Funayama, T | 1 |
| Faro, S | 1 |
| Martens, MG | 1 |
| Maccato, M | 1 |
| Hammill, HA | 1 |
| Roberts, S | 1 |
| Riddle, G | 1 |
| Corrado, ML | 1 |
| Mogabgab, WJ | 1 |
| Holmes, B | 1 |
| Murray, M | 1 |
| Beville, R | 1 |
| Lutz, FB | 1 |
| Tack, KJ | 1 |
| Batteiger, BE | 1 |
| White, A | 1 |
| Sutthijumroon, S | 1 |
| Tungphaisal, S | 1 |
| Kumamoto, Y | 1 |
| Sakai, S | 1 |
| Hirose, T | 1 |
| Tsunekawa, T | 1 |
| Machida, T | 1 |
| Kiyota, H | 1 |
| Okazaki, T | 1 |
| Kishi, H | 1 |
| Higashihara, E | 1 |
| Aso, Y | 1 |
1 review available for ofloxacin and Uterine Cervicitis
| Article | Year |
|---|---|
The clinical experience with ofloxacin in the treatment of sexually transmitted diseases.
Topics: Chlamydia Infections; Chlamydia trachomatis; Female; Gonorrhea; Humans; Ofloxacin; Pelvic Inflammato | 1991 |
10 trials available for ofloxacin and Uterine Cervicitis
| Article | Year |
|---|---|
[Clinical study of levofloxacin 500 mg qd in the treatment of cervicitis and intrauterine infections caused by Chlamydia trachomatis].
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Chlamydia Infections; Chlamydia trachomatis; Dru | 2011 |
Randomized trial of trovafloxacin and ofloxacin for single-dose therapy of gonorrhea. Trovafloxacin Gonorrhea Study Group.
Topics: Adolescent; Adult; Anti-Infective Agents; Double-Blind Method; Female; Fluoroquinolones; Gonorrhea; | 1998 |
Evaluation of two clinical protocols for the management of women with vaginal discharge in southern Thailand.
Topics: Adult; Anti-Infective Agents; Candidiasis, Vulvovaginal; Clinical Protocols; Doxycycline; Female; Go | 1998 |
[Effects of levofloxacin once-a-day therapy on uterine cervicitis].
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Chlamydia Infections; Drug Administration Schedule; | 1999 |
Interrelationships of bacterial vaginosis and cervical inflammation.
Topics: Administration, Oral; Administration, Topical; Adult; Anti-Bacterial Agents; Anti-Infective Agents; | 2002 |
Effectiveness of ofloxacin in the treatment of Chlamydia trachomatis and Neisseria gonorrhoeae cervical infection.
Topics: Adolescent; Adult; Chlamydia Infections; Chlamydia trachomatis; Doxycycline; Drug Evaluation; Female | 1991 |
Randomized comparison of ofloxacin and doxycycline for chlamydia and ureaplasma urethritis and cervicitis.
Topics: Chlamydia Infections; Chlamydia trachomatis; Doxycycline; Female; Humans; Male; Mycoplasmatales Infe | 1990 |
Efficacy and safety of ofloxacin in the treatment of nongonococcal sexually transmitted disease.
Topics: Chlamydia Infections; Chlamydia trachomatis; Doxycycline; Female; Humans; Male; Ofloxacin; Random Al | 1989 |
Evaluation of ofloxacin in the treatment of mucopurulent cervicitis: response of chlamydia-positive and chlamydia-negative forms.
Topics: Adult; Chlamydia Infections; Chlamydia trachomatis; Dose-Response Relationship, Drug; Female; Humans | 1989 |
[Efficacy of ofloxacin in sexually transmitted male urethritis and cervicitis].
Topics: Adult; Chlamydia Infections; Chlamydia trachomatis; Drug Evaluation; Female; Gonorrhea; Humans; Male | 1988 |
5 other studies available for ofloxacin and Uterine Cervicitis
| Article | Year |
|---|---|
Pelvic inflammatory disease in the adolescent: understanding diagnosis and treatment as a health care provider.
Topics: Adolescent; Anti-Bacterial Agents; Arkansas; Ceftriaxone; Centers for Disease Control and Prevention | 2013 |
[Relationship between the endocervical mycoplasma infection and spontaneous abortion due to early embryonic death].
Topics: Abortion, Spontaneous; Adult; Doxycycline; Female; Humans; Microbial Sensitivity Tests; Mycoplasma; | 2004 |
[Measurement of antibody titers to chlamydial infection and effects of levofloxacin in cystic cervicitis and chlamydial infection].
Topics: Actihaemyl; Administration, Oral; Adolescent; Aged; Anti-Bacterial Agents; Anti-Infective Agents; An | 1997 |
Concentration of levofloxacin in cervical mucus and its clinical effects on cervicitis.
Topics: Adult; Anti-Infective Agents; Cervix Mucus; Chlamydia trachomatis; Female; Humans; Levofloxacin; Mid | 1997 |
[Levofloxacin in obstetrics and gynecology].
Topics: Adult; Drug Evaluation; Endometritis; Female; Humans; Levofloxacin; Middle Aged; Ofloxacin; Pelvic I | 1992 |